Bivalirudin antithrombotics  

Hirulog-1 Hirulog Angiomax      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathMajor bleeding

acute coronary syndrome

ACUITY (biva alone vs hep+aGP2b3a), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsLow risk of bias suggesting19%-23%
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006    NCTbivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsLow risk of bias negative13%-6%
PROTECT-TIMI 30, 2006      NCTbivalirudineptifibatide + heparinExploratory -
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
BAT (Bittl), 1995     bivalirudinheparinLow risk of bias suggesting
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007         bivalirudinheparin + GP2b3a inhibitorssuggesting19%-48%
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007     bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsnegative28%11%

acute myocardial infarction

HERO, 1997     bivalirudinheparinLow risk of bias suggesting

percutaneous coronary intervention

REPLACE-2, 2003         bivalirudinheparin + GP2b3a inhibitorsLow risk of bias -
HORIZONS-AMI (Stone), 2008        NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias suggesting-34%-39%
ACUITY (Stone) (bivalirudin alone), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias -
Kleiman, 2002     bivalirudin + eptifibatideheparin + GP2b3a inhibitorsExploratory -
ISAR-REACT 3, 2008    NCTbivalirudinUFHLow risk of bias -
REPLACE-1, 2004     bivalirudinUFHExploratory negative-100%
BAT (Bittl), 1995             bivalirudinUFHLow risk of bias suggesting123%-61%
ARMYDA BIVALVE   bivalirudinUFH -
NAPLES (Tavano), 2009     bivalirudinUFH plus tirofibanRisk of bias suggesting-75%